“After securing the necessary amount of plasma from the Regional Blood Donation and Blood Treatment Centers, he started the process of producing anti-SARS-CoV-2 immunoglobulin for clinical trials,” the company announced.
SEE: Authorities treated coronavirus with herbal drink. Effect – a sharp increase in infections
– Out of 150 liters of blood that we obtained for the production of the drug, over 100 come from miners of Jastrzębska Spółka Węglowa. Thanks to this, we collected the right amount of plasma – explained senator Grzegorz Czelej. He called on the EU to establish plasma banks in individual member states.
Start of production of the Polish drug for COVID-19 | a press conference https://t.co/07t538GiJr
— Biomed Lublin S.A. (@BiomedLublin) August 18, 2020
The drug is in the form of an intramuscular injection
The number of antibodies in the plasma of convalescents declines several weeks after recovery. Therefore, plasma uptake should occur at a very early stage, preferably after a second COVID-19 recovery result.
The drug manufactured by Biomed-Lublin is to be in the form of an ampoule and will be administered intramuscularly in injections in a hospital setting. Production is to end in six weeks, then the first batch of the drug (3,000 ampoules) will be transferred to the Institute of Hematology and Transfusion Medicine and the Independent Public Clinical Hospital No. 1 in Lublin for tests. They will last about four months, after which the drug can be submitted for registration and then sold.
The standard drug registration procedure takes about 210 days, and the regulations on combating the coronavirus pandemic allow it to be shortened to 150 days.
The drug can also be administered prophylactically
Head of the Department of Infectious Diseases PSK 1 in Lublin prof. Krzysztof Tomasiewicz emphasized that the coronavirus does not go away and will probably stay longer, so creating an effective form of therapy and prevention is extremely important. He noted that administering convalescent plasma to patients brings very good results, so a drug made from plasma should be effective. Clinical trials will be conducted in cooperation with other clinics in Poland – he announced and assured that the “express pace” will be used.
– Our expectations are really great, optimistic and supported by some experiences. There is a good chance that we will have a drug that will work in a very large proportion of patients – said Tomasiewicz.
Tomasiewicz added that the drug could also be administered prophylactically in a situation where someone, after contact with an infected person, would like to avoid the disease. – It does not conflict with the vaccine concept. The vaccine will ensure safety in the long term, while the immunoglobulin is a preparation that will protect against immediate infection – he emphasized.
SEE: A doctor removed from the profession. She questioned the coronavirus epidemic
The company’s shares rose after the announcement of the information. In the afternoon, they were close to 15 percent. positive. In the morning, one share cost less than PLN 22 and is now worth around PLN 25.5.
–
